These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

626 related articles for article (PubMed ID: 25831238)

  • 1. Heterogeneous chromosome 12p deletion is an independent adverse prognostic factor and resistant to bortezomib-based therapy in multiple myeloma.
    Li F; Xu Y; Deng P; Yang Y; Sui W; Jin F; Hao M; Li Z; Zang M; Zhou D; Gu Z; Ru K; Wang J; Cheng T; Qiu L
    Oncotarget; 2015 Apr; 6(11):9434-44. PubMed ID: 25831238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical characteristics and prognostic values of 1p32.3 deletion detected through fluorescence in situ hybridization in patients with newly diagnosed multiple myeloma: a single-center study in China.
    Wang H; Meng H; Wang J; Lou Y; Zhou Y; Lin P; Li F; Liu L; Xu H; Yang M; Jin J
    Front Med; 2020 Jun; 14(3):327-334. PubMed ID: 31784918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Additional genetic abnormalities significantly worsen poor prognosis associated with 1q21 amplification in multiple myeloma patients.
    Grzasko N; Hus M; Pluta A; Jurczyszyn A; Walter-Croneck A; Morawska M; Chocholska S; Hajek R; Dmoszynska A
    Hematol Oncol; 2013 Mar; 31(1):41-8. PubMed ID: 22674819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prognostic Impact of 1q21 Amplification in Newly Diagnosed Multiple Myeloma Patients Receiving Bortezomib-Based First-Line Treatment].
    Deng P; Zhou YL; Wei YL; Li P; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1696-1701. PubMed ID: 29262900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion.
    Sagaster V; Ludwig H; Kaufmann H; Odelga V; Zojer N; Ackermann J; Küenburg E; Wieser R; Zielinski C; Drach J
    Leukemia; 2007 Jan; 21(1):164-8. PubMed ID: 17096015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical Features and Response to Treatment in Newly Diagnosed Multiple Myeloma Patients with Deletion 17P].
    Liu Y; Ke XY; Wang J; Wang YF; Dong F; Tian L; Wan W; Jing HM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):802-806. PubMed ID: 28641639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history of multiple myeloma with de novo del(17p).
    Lakshman A; Painuly U; Rajkumar SV; Ketterling RP; Kapoor P; Greipp PT; Gertz MA; Buadi FK; Lacy MQ; Dingli D; Dispenzieri A; Fonder AL; Hayman SR; Hobbs MA; Gonsalves WI; Hwa YL; Leung N; Go RS; Lin Y; Kourelis TV; Warsame R; Lust JA; Russell SJ; Zeldenrust SR; Kyle RA; Kumar SK
    Blood Cancer J; 2019 Mar; 9(3):32. PubMed ID: 30846679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.
    Duru AD; Sutlu T; Wallblom A; Uttervall K; Lund J; Stellan B; Gahrton G; Nahi H; Alici E
    PLoS One; 2015; 10(9):e0138248. PubMed ID: 26378933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study.
    Oh S; Koo DH; Kwon MJ; Kim K; Suh C; Min CK; Yoon SS; Shin HJ; Jo DY; Kwak JY; Kim JS; Sohn SK; Joo YD; Eom HS; Kim SH; Kim YS; Kim C; Mun YC; Kim H; Lee DS; Lee JH;
    Ann Hematol; 2014 Aug; 93(8):1353-61. PubMed ID: 24671365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma.
    Chang H; Trieu Y; Qi X; Xu W; Stewart KA; Reece D
    Leuk Res; 2007 Jun; 31(6):779-82. PubMed ID: 16996589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytogenetics and Survival of Multiple Myeloma: Isolated and Combined Effects.
    Sergentanis TN; Kastritis E; Terpos E; Dimopoulos MA; Psaltopoulou T
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):335-40. PubMed ID: 27101987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LncRNA PRAL is closely related to clinical prognosis of multiple myeloma and the bortezomib sensitivity.
    Xiao G; Li Y; Wang Y; Zhao B; Zou Z; Hou S; Jia X; Liu X; Yao Y; Wan J; Xiong H
    Exp Cell Res; 2018 Sep; 370(2):254-263. PubMed ID: 29944867
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-15a/16-1 cluster located at chromosome 13q14 is down-regulated but displays different expression pattern and prognostic significance in multiple myeloma.
    Li F; Xu Y; Deng S; Li Z; Zou D; Yi S; Sui W; Hao M; Qiu L
    Oncotarget; 2015 Nov; 6(35):38270-82. PubMed ID: 26516702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p).
    Avet-Loiseau H; Leleu X; Roussel M; Moreau P; Guerin-Charbonnel C; Caillot D; Marit G; Benboubker L; Voillat L; Mathiot C; Kolb B; Macro M; Campion L; Wetterwald M; Stoppa AM; Hulin C; Facon T; Attal M; Minvielle S; Harousseau JL
    J Clin Oncol; 2010 Oct; 28(30):4630-4. PubMed ID: 20644101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib.
    Chen MH; Qi C; Reece D; Chang H
    Hum Pathol; 2012 Jun; 43(6):858-64. PubMed ID: 22047644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An abnormal nonhyperdiploid karyotype is a significant adverse prognostic factor for multiple myeloma in the bortezomib era.
    Tan D; Teoh G; Lau LC; Lim A; Lim TH; Yap KC; Premalatha P; Lao ZT; Wee N; Choo C; Wee HC; Su S; Lee YS; Lee LH; Hwang W; Goh YT
    Am J Hematol; 2010 Oct; 85(10):752-6. PubMed ID: 20721886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Characteristics and Prognosis of MAF Deletion in Chinese Patients With Multiple Myeloma.
    Wang Y; Li Q; Xing S; Zhang H; Li D
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e545-e550. PubMed ID: 31262667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain(1)(q21) is an unfavorable genetic prognostic factor for patients with relapsed multiple myeloma treated with thalidomide but not for those treated with bortezomib.
    Smetana J; Berankova K; Zaoralova R; Nemec P; Greslikova H; Kupska R; Mikulasova A; Frohlich J; Sevcikova S; Zahradova L; Krejci M; Sandecka V; Almasi M; Kaisarova P; Melicharova H; Adam Z; Penka M; Jarkovsky J; Jurczyszyn A; Hajek R; Kuglik P
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):123-30. PubMed ID: 23291040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1q21 Gain Combined with High-Risk Factors Is a Heterogeneous Prognostic Factor in Newly Diagnosed Multiple Myeloma: A Multicenter Study in China.
    Li X; Chen W; Wu Y; Li J; Chen L; Fang B; Feng Y; Liu J; Chen M; Gu J; Huang B; Li J
    Oncologist; 2019 Nov; 24(11):e1132-e1140. PubMed ID: 31455749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical characteristics and prognosis of IGH deletion in multiple myeloma.
    He H; Fu W; Jiang H; Du J; Zhou L; Zhang C; Xi H; Li R; Hou J
    Leuk Res; 2015 May; 39(5):515-9. PubMed ID: 25817540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.